Wall Street brokerages expect that Denali Therapeutics Inc (NASDAQ:DNLI) will post earnings per share of ($0.49) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Denali Therapeutics’ earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.57). Denali Therapeutics reported earnings per share of ($0.38) in the same quarter last year, which suggests a negative year over year growth rate of 28.9%. The business is expected to issue its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Denali Therapeutics will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.47) to ($1.28). For the next year, analysts forecast that the company will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.65) to ($0.96). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, August 6th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The business had revenue of $4.20 million for the quarter, compared to the consensus estimate of $4.52 million. Denali Therapeutics had a negative return on equity of 11.03% and a negative net margin of 40.78%.
In other news, COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $18.77, for a total transaction of $140,775.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ryan J. Watts sold 18,333 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.07, for a total value of $349,610.31. The disclosure for this sale can be found here. Insiders have sold 94,166 shares of company stock worth $1,847,878 in the last ninety days. 21.20% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. lifted its stake in shares of Denali Therapeutics by 18.3% in the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock valued at $153,773,000 after purchasing an additional 1,145,003 shares during the period. BlackRock Inc. raised its stake in Denali Therapeutics by 13.3% during the 2nd quarter. BlackRock Inc. now owns 5,154,097 shares of the company’s stock worth $106,999,000 after buying an additional 604,766 shares during the period. Wasatch Advisors Inc. raised its stake in Denali Therapeutics by 21.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 996,147 shares of the company’s stock worth $20,680,000 after buying an additional 175,243 shares during the period. Pictet Asset Management Ltd. acquired a new position in Denali Therapeutics during the 2nd quarter worth approximately $15,349,000. Finally, Northern Trust Corp raised its stake in Denali Therapeutics by 1.0% during the 2nd quarter. Northern Trust Corp now owns 620,050 shares of the company’s stock worth $12,873,000 after buying an additional 6,063 shares during the period. 71.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of DNLI stock traded up $0.54 during trading hours on Friday, hitting $18.16. 160,023 shares of the company’s stock were exchanged, compared to its average volume of 364,689. The stock’s 50-day moving average is $20.20 and its 200-day moving average is $21.49. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.65 and a quick ratio of 10.66. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -46.56 and a beta of 2.12. Denali Therapeutics has a 52 week low of $13.78 and a 52 week high of $28.86.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: Do equity income investments outperform growth and income investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.